

3 April 2026

## Atopic Dermatitis

**Question 1. How many patients were treated in the last 4 months (December to March 2026) by the dermatology department with each of the following products:**

- Abrocitinib 11
- Acitretin 0
- Alitretinoin 0
- Azathioprine 0
- Baricitinib <5
- Ciclosporin 0
- Dupilumab 270
- Lebrikizumab 11
- Methotrexate 0
- Mycophenolate mofetil 0
- Pimecrolimus 0
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only 0
- Tacrolimus ointment 0
- Tralokinumab 0
- Upadacitinib 48
- Nemolizumab <5

**Question 2. In the last 4 months, how many new patients have been initiated\* on the following treatments by the dermatology department**

- Abrocitinib <5
- Baricitinib 0
- Dupilumab 29
- Lebrikizumab <5
- Tralokinumab <5
- Upadacitinib <5
- Nemolizumab <5

**\*Patients are considered 'new patients initiated' on a treatment if they have not been previously treated with any of the other named treatments above since 1st April 2025 prior to initiation.**

**e.g. Patient initiated on Lebrikizumab in Dec 2025 - March 2026 (has not previously been treated with Abro, Bari, Dupi, Tralo, Upada, Nemo since March 2025)**

**3 April 2026**

**Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:**

- **6 months to 5** <5
- **Age 6-11** 19
- **Age 12-17** 35
- **Age 18 and above** 288

**Question 4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:**

- **Dupilumab** 7
- **Nemolizumab** <5

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.